StockData
IGC Pharma, Inc. logo

IGC Pharma, Inc. (IGC) stock

IGCNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q1 FY2027, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 2/3011% above fair value
$0.19+0.01 (+7.37%)

Close on Nov 17, 2026Market cap $19.43MP/E –Yield –

IGC Pharma r&d expenses

Research and development expenses are spending on new products and technology.

IGC Pharma's R&D Expenses for the twelve months ending Jun 30, 2026 was $5.73M, up 58.5% year over year. For fiscal 2025 it was $3.66M, down 3.1% from the year before. The highest annual figure on record is $3.77M in fiscal 2024.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Mar 31, 2025$3.66M-3.1%
FY2024Mar 31, 2024$3.77M+9.0%
FY2023Mar 31, 2023$3.46M+48.5%
FY2022Mar 31, 2022$2.33M+150.8%
FY2021Mar 31, 2021$929.00K-8.1%
FY2020Mar 31, 2020$1.01M-19.5%
FY2019Mar 31, 2019$1.26M+816.8%
FY2018Mar 31, 2018$137.00K–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

Periods
PeriodPeriod endValueChange
Q1 FY2027CQ2 2026Jun 30, 2026$1.39M+63.3%
Q4 FY2026CQ1 2026Mar 31, 2026$1.27M+27.6%
Q3 FY2026CQ4 2025Dec 31, 2025$1.48M+73.9%
Q2 FY2026CQ3 2025Sep 30, 2025$1.59M+73.2%
Q1 FY2026CQ2 2025Jun 30, 2025$851.00K-4.3%
Q4 FY2025CQ1 2025Mar 31, 2025$997.00K+16.6%
Q3 FY2025CQ4 2024Dec 31, 2024$852.00K-5.6%
Q2 FY2025CQ3 2024Sep 30, 2024$917.00K-27.7%
Q1 FY2025CQ2 2024Jun 30, 2024$889.00K+19.0%
Q4 FY2024CQ1 2024Mar 31, 2024$855.00K+73.4%
Q3 FY2024CQ4 2023Dec 31, 2023$903.00K+12.0%
Q2 FY2024CQ3 2023Sep 30, 2023$1.27M+65.1%
Q1 FY2024CQ2 2023Jun 30, 2023$747.00K-46.4%
Q4 FY2023CQ1 2023Mar 31, 2023$493.00K-60.0%
Q3 FY2023CQ4 2022Dec 31, 2022$806.00K+113.8%
Q2 FY2023CQ3 2022Sep 30, 2022$768.00K+178.3%
Q1 FY2023CQ2 2022Jun 30, 2022$1.39M+214.0%
Q4 FY2022CQ1 2022Mar 31, 2022$1.23M+269.2%
Q3 FY2022CQ4 2021Dec 31, 2021$377.00K+144.8%
Q2 FY2022CQ3 2021Sep 30, 2021$276.00K+26.0%
Q1 FY2022CQ2 2021Jun 30, 2021$444.00K+100.0%
Q4 FY2021CQ1 2021Mar 31, 2021$334.00K+35.2%
Q3 FY2021CQ4 2020Dec 31, 2020$154.00K-47.8%
Q2 FY2021CQ3 2020Sep 30, 2020$219.00K-1.4%
Q1 FY2021CQ2 2020Jun 30, 2020$222.00K-10.1%
Q4 FY2020CQ1 2020Mar 31, 2020$247.00K-69.5%
Q3 FY2020CQ4 2019Dec 31, 2019$295.00K+77.7%
Q2 FY2020CQ3 2019Sep 30, 2019$222.00K-20.1%
Q1 FY2020CQ2 2019Jun 30, 2019$247.00K+586.1%
Q4 FY2019CQ1 2019Mar 31, 2019$811.00K+926.6%
Q3 FY2019CQ4 2018Dec 31, 2018$166.00K–
Q2 FY2019CQ3 2018Sep 30, 2018$278.00K+256.4%
Q1 FY2019CQ2 2018Jun 30, 2018$36.00K-36.3%
Q4 FY2018CQ1 2018Mar 31, 2018$79.00K–
Q3 FY2018CQ4 2017Dec 31, 2017$0–
Q2 FY2018CQ3 2017Sep 30, 2017$78.00K–
Q1 FY2018CQ2 2017Jun 30, 2017$56.54K–

More IGC Pharma figures

See a number that looks wrong?